imatinib mesylate has been researched along with Fibrosarcoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Charvát, M; Grossmann, P; Hrudka, J; Kinkor, Z | 1 |
| Altintas, L; Degim, IT; Demirbolat, GM; Yilmaz, S | 1 |
| Altıntaş, L; Arsoy, T; Çoban, Ö; Değim, Z; Sözmen, M; Yılmaz, Ş | 1 |
| Andersson, P; Cao, Y; Feng, N; Hosaka, K; Jensen, L; Larsson, O; Li, X; Lim, S; Nakamura, M; Ohhashi, T; Rouhi, P; Seki, T; Xue, Y; Yang, X; Yang, Y | 1 |
| Bracha, S; Goodall, CP; Helfand, SC; Löhr, CV; Marley, K; Milovancev, M | 1 |
| Alexandru, D; Bota, DA; Van Horn, DK | 1 |
| Casali, PG; Collini, P; Conca, E; Gronchi, A; Keslair, F; Marrari, A; Morosi, C; Negri, T; Palassini, E; Pedeutour, F; Pilotti, S; Stacchiotti, S | 1 |
| Buchdunger, E; Dal Cin, P; Dumanski, JP; Heldin, CH; O'Brien, KP; Ostman, A; Pietras, K; Shimizu, A; Sjöblom, T | 1 |
8 other study(ies) available for imatinib mesylate and Fibrosarcoma
| Article | Year |
|---|---|
Dermatofibrosarcoma protuberans with fibrosarcomatous transformation: a case report.
Topics: Dermatofibrosarcoma; Fibrosarcoma; Humans; Imatinib Mesylate; Male; Skin Neoplasms; Translocation, Genetic | 2020 |
Development of Orally Applicable, Combinatorial Drug-Loaded Nanoparticles for the Treatment of Fibrosarcoma.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Caco-2 Cells; Chitosan; Drug Compounding; Drug Delivery Systems; Fibrosarcoma; Humans; Imatinib Mesylate; Ketoprofen; Male; Mice, Inbred BALB C; Nanocapsules; Tromethamine | 2018 |
Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Cell Proliferation; Cell Survival; Drug Compounding; Fibrosarcoma; Humans; Imatinib Mesylate; Ketoprofen; Liposomes; Male; Mice; Nanoparticles; Particle Size; Tromethamine; Xenograft Model Antitumor Assays | 2019 |
Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Becaplermin; Benzamides; Carcinoma, Lewis Lung; Cell Movement; Cell Proliferation; Fibrosarcoma; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Integrin alpha1beta1; Lung Neoplasms; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Pericytes; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Dog Diseases; Dogs; Doxorubicin; Fibrosarcoma; Imatinib Mesylate; Mouth Neoplasms; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Secondary fibrosarcoma of the brain stem treated with cyclophosphamide and Imatinib.
Topics: Antineoplastic Agents; Benzamides; Brain Stem Neoplasms; Cyclophosphamide; Fibrosarcoma; Glial Fibrillary Acidic Protein; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Mesencephalon; Middle Aged; Piperazines; Pyrimidines; S100 Proteins | 2010 |
Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Female; Fibrosarcoma; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Retrospective Studies | 2011 |
Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.
Topics: Adult; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; Child, Preschool; Dermatofibrosarcoma; Female; Fibrosarcoma; Giant Cell Tumors; Growth Inhibitors; Humans; Imatinib Mesylate; Infant; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms; Xenograft Model Antitumor Assays | 2001 |